VivoSeq
Other

Microsatellite Stable

0

Pipeline Programs↗

1

Active Trials↗

1

Companies Involved↗

Microsatellite Stable is an early-stage landscape with 0 programs across 1 company. The most active players are GSK.

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

GSK logo

GSK

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

4

clinical trials

Completed2 · 50%
Recruiting1 · 25%
Unknown status1 · 25%

Clinical Trials

Trial Activity

A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer
Recruiting·GSK logoGSK·Phase 2·NCT06567782·120 enrolled
Avelumab Combined With Cetuximab and Irinotecan for Treatment Refractory Metastatic Colorectal Microsatellite Stable Cancer
Unknown status·CCliniques universitaires Saint-Luc- Université Catholique de Louvain·Phase 2·NCT03608046·59 enrolled
Combined PD-1 and CCR5 Inhibition for the Treatment of Refractory Microsatellite Stable mCRC
Completed·UUniversity Hospital Heidelberg·Phase 1·NCT03274804·20 enrolled
Study of Durvalumab (MEDI4736) After Chemo-Radiation for Microsatellite Stable Stage II-IV Rectal Cancer
Completed·NNSABP Foundation Inc·Phase 2·NCT03102047·45 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)